Q2 2020 Results

Investor News August 04, 2020

Second quarter of 2020:

Bayer: Solid performance despite COVID-19 impact

Ensuring employee safety and maintaining supply chains remain top priorities / Group sales decline by 2.5 percent (Fx & portfolio adj.) to 10.054 billion euros / EBITDA before special items up 5.6 percent to 2.883 billion euros / Crop Science reports operational growth / Sales and earnings at Pharmaceuticals down mainly due to volume-based procurement policy in China and COVID-19 / Sales at Consumer Health decline slightly (Fx & portfolio adj.) after strong demand in first quarter / Net loss of 9.548 billion euros due to special items for litigations - agreements in major legacy Monsanto litigation / Core earnings per share increase by 5.3 percent to 1.59 euros / Free cash flow rises to 1.402 billion euros / Outlook adjusted for COVID-19 impact MORE

Investor Conference Call

Tuesday, August 4, 2020
Start at approx. 2:00 p.m. CEST (12:00 noon UTC)